Trial
NCT04625153
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
RemeGen Co., Ltd.
Collaborators
—
Condition
Multiple Sclerosis, Relapsing-Remitting
Intervention
RC18 160mg
Why stopped
Sponsor Strategic Priority Adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-13